PTTG1 and neoplasm: Following intratumoral administration of 1 × 109 plaque-forming units (pfu) of Ad-PTTG-1-siRNA into the mice, tumor regression study demonstrated that Ad-PTTG-1-siRNA-treated groups regressed 84% of tumor volume in comparison to the control groups, suggesting that Ad-PTTG1-siRNA may serve a new paradigm for treating human cancers [375].